Open access
Open access
Powered by Google Translator Translator

Hematology (all articles)

RCT supports the use of therapeutic heparin in moderately ill patients admitted to the hospital with Covid-19.

17 Oct, 2021 | 21:35h | UTC

Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial – The BMJ

Commentary: High-dose of readily available blood thinner reduces risk of death for moderately ill COVID-19 patients – St. Michael’s Hospital

Related studies (some conflicting results)

RCT: Therapeutic-dose heparin superior to standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19.

Another meta-analysis suggests standard-dose prophylactic anticoagulation is the best option for patients hospitalized with Covid-19.

M-A: Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19 – According to this analysis, standard-dose prophylactic anticoagulation should be the standard of care for hospitalized patients with COVID-19 who do not have an indication for therapeutic anticoagulation, irrespective of disease severity.

RCT: In noncritically ill patients hospitalized with Covid-19, therapeutic-dose anticoagulation with heparin increased the probability of survival to hospital discharge compared with usual-care thromboprophylaxis.

RCT: In critically ill patients with Covid-19, therapeutic anticoagulation with heparin did not result in improved outcomes compared to usual-care pharmacologic thromboprophylaxis.

RCT: In patients hospitalized with Covid-19 with elevated D-Dimer, a full-dose anticoagulation strategy based on rivaroxaban (full-dose heparins in unstable patients) + rivaroxaban to day 30 was not better than prophylactic anticoagulation and increased bleeding risk.

 

Commentary on Twitter

 

Guidelines for anesthesiologists on patient blood management in cardiac surgery.

17 Oct, 2021 | 21:22h | UTC

2021 Clinical Practice Guidelines for Anesthesiologists on Patient Blood Management in Cardiac Surgery – Journal of Cardiothoracic and Vascular Anesthesia

 

Commentary on Twitter

 

ASH 2021 guidelines for stem cell transplantation in patients with sickle cell disease.

14 Oct, 2021 | 09:53h | UTC

American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation – Blood

News release: ASH Releases New Clinical Practice Guidelines on Stem Cell Transplantation in Sickle Cell Disease

Commentary: ASH Issues Guideline on the Use of HSCT for Sickle Cell Disease – HealthDay

 

Systematic Review: Direct oral anticoagulants (DOACs) may be beneficial for people being treated for cancer who have no therapeutic or prophylactic indication for anticoagulation.

14 Oct, 2021 | 09:44h | UTC

Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation – Cochrane Library

 

Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018.

13 Oct, 2021 | 01:21h | UTC

Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018 – Nature Medicine

Invited commentary: Anemia in women — an intractable problem that requires innovative solutions – Nature Medicine

 

RCT: No benefit from antithrombotic therapy (aspirin or apixaban) in outpatients with clinically stable symptomatic COVID-19.

12 Oct, 2021 | 00:28h | UTC

Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial – JAMA

Editorial: Antithrombotic Therapy for Outpatients With COVID-19: Implications for Clinical Practice and Future Research – JAMA

 

Commentary on Twitter

 

D-Dimer testing for the exclusion of pulmonary embolism has limited clinical utility among hospitalized patients with COVID-19 – most patients with or without pulmonary embolism have increased levels.

12 Oct, 2021 | 00:26h | UTC

D-Dimer Testing for the Exclusion of Pulmonary Embolism Among Hospitalized Patients With COVID-19 – JAMA Network Open

Commentary: D-Dimer Level Not Useful for Ruling Out PE in COVID-19 Patients – HealthDay

 

RCT: Therapeutic-dose heparin superior to standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19.

10 Oct, 2021 | 21:53h | UTC

Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial – JAMA Internal Medicine

Invited commentary: Anticoagulant Therapy in Patients Hospitalized With COVID-19 – JAMA Internal Medicine

Related studies (some conflicting results)

Another meta-analysis suggests standard-dose prophylactic anticoagulation is the best option for patients hospitalized with Covid-19.

M-A: Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19 – According to this analysis, standard-dose prophylactic anticoagulation should be the standard of care for hospitalized patients with COVID-19 who do not have an indication for therapeutic anticoagulation, irrespective of disease severity.

RCT: In noncritically ill patients hospitalized with Covid-19, therapeutic-dose anticoagulation with heparin increased the probability of survival to hospital discharge compared with usual-care thromboprophylaxis.

RCT: In critically ill patients with Covid-19, therapeutic anticoagulation with heparin did not result in improved outcomes compared to usual-care pharmacologic thromboprophylaxis.

RCT: In patients hospitalized with Covid-19 with elevated D-Dimer, a full-dose anticoagulation strategy based on rivaroxaban (full-dose heparins in unstable patients) + rivaroxaban to day 30 was not better than prophylactic anticoagulation and increased bleeding risk.

 

Commentary on Twitter

 

State of the Art Review: Advances in acute myeloid leukemia.

8 Oct, 2021 | 10:05h | UTC

Advances in acute myeloid leukemia – The BMJ

 

Commentary on Twitter

 

Series from the Lancet journals: Hematological malignancies in older people.

6 Oct, 2021 | 08:47h | UTC

Homepage: Haematological malignancies in older people – The Lancet Haematology

Commentary: Living longer and better with haematological malignancies: a promise for older adults too? (free registration required)

A comprehensive approach to therapy of haematological malignancies in older patients (free registration required)

Frailty assessment in the care of older people with haematological malignancies

Haematopoietic stem-cell transplantation in older adults: geriatric assessment, donor considerations, and optimisation of care (free registration required)

Palliative care of patients with haematological malignancies: strategies to overcome difficulties via integrated care

Implementation of geriatric haematology programmes for the treatment of older people with haematological malignancies in low-resource settings

 

Review: Inhibition of platelet aggregation after coronary stenting in patients receiving oral anticoagulation.

6 Oct, 2021 | 08:46h | UTC

Inhibition of Platelet Aggregation After Coronary Stenting in Patients Receiving Oral Anticoagulation – Deutsches Ärzteblatt International

 

RCT: Another study shows convalescent plasma does not improve outcomes in critically ill patients with Covid-19.

5 Oct, 2021 | 10:06h | UTC

Effect of Convalescent Plasma on Organ Support–Free Days in Critically Ill Patients With COVID-19 A Randomized Clinical Trial – JAMA

Commentary: Convalescent plasma futile as treatment for critically ill COVID-19 patients, study finds – University of Pittsburgh

Related:

RCT: Convalescent plasma does not improve outcomes and may be harmful to hospitalized patients with COVID-19.

NIH study shows no significant benefit of convalescent plasma for COVID-19 outpatients with early symptoms.

M-A: Convalescent plasma is safe but does not improve outcomes in the treatment of COVID-19.

RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.

 

Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance.

3 Oct, 2021 | 22:59h | UTC

Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance – The BMJ

Original Guidance: NICE COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis.

Related:

Clinical features of vaccine-induced immune thrombocytopenia and thrombosis.

Review: Clinical characteristics and pharmacological management of COVID-19 vaccine–induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis.

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.

Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (several articles and resources on the subject)

 

Systematic Review: Does testing for cancer in people with unprovoked blood clots in the legs and lungs reduce cancer- and blood clot-related death and illness?

3 Oct, 2021 | 22:33h | UTC

Summary: Does testing for cancer in people with unprovoked blood clots in the legs and lungs reduce cancer- and blood clot-related death and illness? – Cochrane Library

Original article: Effect of testing for cancer on cancer‐ or venous thromboembolism (VTE)‐related mortality and morbidity in people with unprovoked VTE – Cochrane Library

 

Another meta-analysis suggests standard-dose prophylactic anticoagulation is the best option for patients hospitalized with Covid-19.

1 Oct, 2021 | 10:35h | UTC

A Systematic Review and a Meta-Analysis Comparing Prophylactic and Therapeutic Low Molecular Weight Heparins for Mortality Reduction in 32,688 COVID-19 Patients – Frontiers in Pharmacology

Related: M-A: Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19 – According to this analysis, standard-dose prophylactic anticoagulation should be the standard of care for hospitalized patients with COVID-19 who do not have an indication for therapeutic anticoagulation, irrespective of disease severity.

 

AGA Clinical Practice Guideline on the Management of Coagulation Disorders in Patients With Cirrhosis.

29 Sep, 2021 | 10:07h | UTC

AGA Clinical Practice Guideline on the Management of Coagulation Disorders in Patients With Cirrhosis – Gastroenterology

See also: AGA Technical Review on Coagulation in Cirrhosis – Gastroenterology

 

Podcast: Neutropenic Fever.

28 Sep, 2021 | 08:52h | UTC

#288 LIVE! Neutropenic Fever featuring Dr. Susan Seo – The Curbsiders

 

Evaluating the Cost-effectiveness of Prehospital Plasma Transfusion in Unstable Trauma Patients: A Secondary Analysis of the PAMPer Trial.

26 Sep, 2021 | 21:54h | UTC

Evaluating the Cost-effectiveness of Prehospital Plasma Transfusion in Unstable Trauma Patients: A Secondary Analysis of the PAMPer Trial – JAMA Surgery (free for a limited period)

Commentaries:

CHEERS to You on a Well-done Cost-effectiveness Analysis of Prehospital Plasma for Helicopter Resuscitation of Patients With Traumatic Shock – JAMA Surgery (free for a limited period)

Prehospital Plasma: A Cheap, Effective Way to Save Trauma Patients’ Lives? – BreakingMed

 

Commentary on Twitter

 

M-A: Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19 – According to this analysis, standard-dose prophylactic anticoagulation should be the standard of care for hospitalized patients with COVID-19 who do not have an indication for therapeutic anticoagulation, irrespective of disease severity.

21 Sep, 2021 | 09:54h | UTC

Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials – European Heart Journal – Cardiovascular Pharmacotherapy

 

Commentary on Twitter (thread – click for more)

 

Review: Transfusion-related acute lung injury in the perioperative patient.

21 Sep, 2021 | 08:56h | UTC

Transfusion-related Acute Lung Injury in the Perioperative Patient – Anesthesiology

 

RCT: Rivaroxaban does not have an impact on disease progression and symptoms resolution in high-risk adults with mild COVID-19.

17 Sep, 2021 | 10:19h | UTC

Randomized study of rivaroxaban vs. placebo on disease progression and symptoms resolution in high-risk adults with mild COVID-19 – Clinical Infectious Diseases

 

Review | Thrombophilia testing in the era of direct oral anticoagulants.

17 Sep, 2021 | 09:53h | UTC

Thrombophilia testing in the era of direct oral anticoagulants – Clinical Medicine Journal

 

Case series: Vaccine-induced thrombocytopenia with severe headache may precede cerebral venous sinus thrombosis by several days – patients with severe headache 5 to 20 days after adenovirus vector vaccination against Covid-19 should undergo immediate testing for thrombocytopenia and d-dimer levels and, if available, testing for anti–PF4–heparin IgG antibodies.

16 Sep, 2021 | 10:14h | UTC

Vaccine-Induced Thrombocytopenia with Severe Headache – New England Journal of Medicine

 

Commentary on Twitter

 

State of the Art Review: Eosinophils in Health and Disease.

16 Sep, 2021 | 09:59h | UTC

Eosinophils in Health and Disease: A State-of-the-Art Review – Mayo Clinic Proceedings

 

Review: Is there an optimal antiplatelet strategy after gastrointestinal bleeding in patients with coronary artery disease?

16 Sep, 2021 | 09:57h | UTC

Is There an Optimal Antiplatelet Strategy after Gastrointestinal Bleeding in Patients with Coronary Artery Disease? – Cardiology

 

Stay Updated in Your Specialty

No spam, just news.